The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
Vertex has really been getting a positive roll on its clinical studies for VX-950 so far. It may be the first of a new generation of Hepatitis c therapies to hit the market, and that has investors very excited. Not to mention patients.
Continue reading »Yet another treatment in the pipeline. But, this one is at the very beginning stages. They are still trying to discover whether it is even safe (let alone effective). Stay tuned...
Continue reading »This is a drug being developed in Canada in cooperation with Schering Plough. Seeing as Schering is currently the number... View Article
Continue reading »This is an unusual post for us. First we have the official press release on a new approach to HCV and then the comments from an interested observer. We think you will find this information to be of great interest.
Continue reading »Here is another report of progress being made with a unique approach to treatment of the Hepatitis c virus. With so many companies working on a treatment, the odds are on our side that one will be proven and approved in the next 5 years or so.
Continue reading »This is an article from Forbes. Again, the business side of this disease can provide quite a bit of information for us patients. The fact that Credit Suisse First Boston likes VX-950 is certainly a good sign.
Continue reading »The following article is from Pharmaceutical Business Review. I don’t know why, exactly, but I love it when these guys... View Article
Continue reading »Albuferon is an interferon that can be taken once a month and has less side effects than other interferons. It is closer to approval than other drugs being developed and seems like a better option than existing therapy.
Continue reading »This is an update on the earlier story about VX-950. I’ve put it up here because it gives a bit... View Article
Continue reading »What I find most significant about this report is that genotype 1 patients got somewhere between a 48% and 54%... View Article
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
